赛诺菲确认:长效降脂药阿利西尤单抗在中国已停供

健识局
Aug 04

8月4日,一份《关于“波立达”(阿利西尤单抗注射液)的告知函》在业内流传。《告知函》中指出,赛诺菲将停止PCSK9抑制剂阿利西尤单抗在中国市场的推广。赛诺菲向健识局证实了该消息的真实性,表示由于全球原料供应形势紧张的影响,阿利西尤单抗在中国市场面临供应方面的挑战。阿利西尤单抗是一款PCSK9抑制剂,由赛诺菲和再生元共同开发,赛诺菲负责美国以外市场的商业化销售,2019年12月在中国正式获批上市,并...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10